Your session is about to expire
← Back to Search
SGN-B6A for Advanced Solid Tumors
Study Summary
This trial will study whether a drug called SGN-B6A is safe for people with solid tumors, what its side effects are, and whether it works to treat cancer.
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
- Oral Squamous Cell Carcinoma
- Breast Cancer
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Bladder Cancer
- Cervical Cancer
- Stomach Tumors
- Ovarian Tumors
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a severe lung disease that is not related to your cancer.You have a history of lung disease or low lung function.You have active cancer that has spread to your brain or the covering of your brain and spinal cord.You have taken certain medications before, have existing nerve problems, or have a severe viral, bacterial, or fungal infection that is not under control.You have previously taken certain medications and had severe side effects.You have a detectable disease according to a specific set of guidelines at the beginning of the study.You are able to perform everyday activities without any problem or with only a little limitation due to your cancer.You have had another type of cancer in the last 3 years, or still have signs of a previous cancer.You must have a confirmed diagnosis of advanced cancer that cannot be removed by surgery.You have a disease that has come back, not responded to treatment, or you cannot tolerate the standard treatments available.You have a type of cancer that has come back, not responded to treatment, or you can't tolerate the treatment, and you have already been treated with a platinum-based therapy and a PD-1/PD-L1 inhibitor if it applies to you.You have not received any previous treatment for advanced cancer.You have esophageal squamous cell carcinoma.Reason for the diseaseYou have advanced breast cancer that does not have a specific type of protein called HER2.You have head and neck squamous cell cancer.You do not have non-small cell lung cancer.You must have a confirmed, advanced type of cancer and have tried other treatments that didn't work or had side effects.
- Group 1: Part A: Dose escalation
- Group 2: Part B: Dose expansion
- Group 3: Part C: SGN-B6A combination therapy in NSCLC, HNSCC, ESCC
- Group 4: Part D: SGN-B6A combination therapy in 1L NSCLC
- Group 5: Part D: SGN-B6A combination therapy in 1L HNSCC
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned SGN-B6A as a legitimate remedy?
"Due to the limited data on efficacy and safety, our team has rated SGN-B6A's risk level at a 1 out of 3. This is because this clinical trial belongs to Phase 1."
Are there any open enrollments for this clinical experiment currently?
"Indeed, the clinical trial is still open for enrolment. According to records on clinicaltrials.gov, this experiment was published in June 2020 and its latest update occurred in November 2022."
How many sites are currently offering participation in this research?
"This medical experiment is being conducted at 8 different sites, situated in Houston, Portland, and San Antonio as well as several other locations. To reduce the burden of travel for participants, it would be beneficial to select a location close by when signing up."
How many individuals have been enrolled in this investigational research?
"In order to successfully conduct this medical trial, 355 eligible patients must be enrolled. This can occur at various locations such as MD Anderson Cancer Center / University of Texas in Houston and Providence Portland Medical Center in Oregonf Texas in Houston and Providence Portland Medical Center in Oregon."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger